GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (STU:VM4) » Definitions » Additional Paid-In Capital

Vanda Pharmaceuticals (STU:VM4) Additional Paid-In Capital : €661.2 Mil(As of Mar. 2025)


View and export this data going back to 2006. Start your Free Trial

What is Vanda Pharmaceuticals Additional Paid-In Capital?


Vanda Pharmaceuticals's quarterly additional paid-in capital increased from Sep. 2024 (€639.6 Mil) to Dec. 2024 (€680.6 Mil) but then stayed the same from Dec. 2024 (€680.6 Mil) to Mar. 2025 (€661.2 Mil).

Vanda Pharmaceuticals's annual additional paid-in capital declined from Dec. 2022 (€647.8 Mil) to Dec. 2023 (€642.2 Mil) but then increased from Dec. 2023 (€642.2 Mil) to Dec. 2024 (€680.6 Mil).


Vanda Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Vanda Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals Additional Paid-In Capital Chart

Vanda Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 534.55 592.26 647.81 642.15 680.63

Vanda Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 647.55 656.66 639.57 680.63 661.15

Vanda Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Vanda Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Vanda Pharmaceuticals Business Description

Traded in Other Exchanges
Address
2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Vanda Pharmaceuticals Headlines

No Headlines